Aktienanalyse zu Quest Diagnostics Inc (DGX)DGXQuest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. It provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and its connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. Its other customers include health plans, employers, emerging retail healthcare providers, government agencies, and others. Its services are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Quest Diagnostics Inc is a good buy right now due to its strong recent performance and positive growth outlook. The current price is $241.89, with a forward P/E ratio of 19.53, indicating reasonable valuation relative to future earnings. The company reported a 10% revenue growth in Q3 2026, with expectations of over 30% growth in consumer health revenue, which is a significant driver for future performance. However, there is a risk of a potential 1% revenue hit in 2027 due to proposed rate cuts under the PAMA Act, which could impact earnings.

20 analysts cover DGX: 5 rate it Buy, 14 Hold and 1 Sell. The average price target is 203.33.